• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Individualized Antiplatelet Therapy: A Long Way to Go.

作者信息

Han Ya-Ling

机构信息

Department of Cardiology, The General Hospital of Shenyang Military Region, Shenyang, Liaoning 110016, China.

出版信息

Chin Med J (Engl). 2018 Jun 20;131(12):1387-1389. doi: 10.4103/0366-6999.233964.

DOI:10.4103/0366-6999.233964
PMID:29893354
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6006826/
Abstract
摘要

相似文献

1
Individualized Antiplatelet Therapy: A Long Way to Go.个体化抗血小板治疗：任重道远。
Chin Med J (Engl). 2018 Jun 20;131(12):1387-1389. doi: 10.4103/0366-6999.233964.
2
Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.倡导使用 P2Y12 受体抑制剂的心血管精准医学。
Eur Heart J Cardiovasc Pharmacother. 2017 Oct 1;3(4):221-234. doi: 10.1093/ehjcvp/pvw044.
3
Personalizing antiplatelet therapies: What have we learned from recent trials?个体化抗血小板治疗：我们从最近的临床试验中学到了什么？
Platelets. 2018 Mar;29(2):131-139. doi: 10.1080/09537104.2017.1320372. Epub 2017 Jun 19.
4
Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.急性冠状动脉综合征患者个性化抗血小板治疗的成本效益分析
Pharmacogenomics. 2016 May;17(7):701-13. doi: 10.2217/pgs-2016-0008. Epub 2016 May 11.
5
Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome.抗血小板治疗及抗血小板抵抗在急性冠状动脉综合征中的作用。
Thromb Res. 2009 May;124(1):6-13. doi: 10.1016/j.thromres.2009.01.014. Epub 2009 Mar 25.
6
Platelet Function Testing: A Role for Personalised Therapy in Coronary Disease.血小板功能检测：个性化治疗在冠心病中的作用
Curr Pharm Des. 2017;23(9):1315-1327. doi: 10.2174/1381612823666170126160359.
7
Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.急性冠状动脉综合征或经皮冠状动脉介入治疗后双联抗血小板治疗疗程的个体化
Circulation. 2016 May 24;133(21):2094-8. doi: 10.1161/CIRCULATIONAHA.115.021158.
8
Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention.急性冠状动脉综合征和经皮冠状动脉介入治疗患者抗血小板治疗的临床价值。
Biomark Med. 2011 Feb;5(1):9-30. doi: 10.2217/bmm.11.2.
9
Dual antiplatelet therapy duration in patients following percutaneous coronary intervention or after acute coronary syndrome: one size does not fit all.经皮冠状动脉介入治疗后或急性冠状动脉综合征后的患者双联抗血小板治疗持续时间：并非一概而论。
Future Cardiol. 2017 May;13(3):199-201. doi: 10.2217/fca-2017-0017. Epub 2017 May 31.
10
Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.为改善稳定性心绞痛或非ST段抬高型急性冠脉综合征患者在经皮冠状动脉介入治疗前表现出氯吡格雷低反应的预后而进行的个体化抗血小板治疗。
Platelets. 2015;26(6):521-9. doi: 10.3109/09537104.2014.948837. Epub 2014 Aug 28.

本文引用的文献

1
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity.通心络胶囊对急性冠状动脉综合征伴高血小板反应患者的疗效：一项多中心、随机、双盲、安慰剂对照研究
Chin Med J (Engl). 2018 Mar 5;131(5):508-515. doi: 10.4103/0366-6999.226064.
2
Impact of Proton-pump Inhibitors on the Pharmacodynamic Effect and Clinical Outcomes in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: A Propensity Score Analysis.质子泵抑制剂对经皮冠状动脉介入治疗后双联抗血小板治疗患者药效学效应和临床结局的影响：倾向评分分析。
Chin Med J (Engl). 2017 Dec 20;130(24):2899-2905. doi: 10.4103/0366-6999.220304.
3
Recent Evolution of the Treatment of Coronary Artery Disease in China: A Conversation With Ya-Ling Han, MD, PhD.中国冠状动脉疾病治疗的最新进展：与韩雅玲医学博士、哲学博士的对话
Circulation. 2017 Dec 12;136(24):2298-2302. doi: 10.1161/CIRCULATIONAHA.117.032510.
4
Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease.Stanford 型 B 型主动脉夹层合并冠心病患者血管腔内修复术后抗血小板治疗的安全性和必要性。
Chin Med J (Engl). 2017 Oct 5;130(19):2321-2325. doi: 10.4103/0366-6999.215330.
5
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.经皮冠状动脉介入治疗的急性冠状动脉综合征患者的抗血小板治疗降级指导（TROPICAL-ACS）：一项随机、开放标签、多中心试验。
Lancet. 2017 Oct 14;390(10104):1747-1757. doi: 10.1016/S0140-6736(17)32155-4. Epub 2017 Aug 28.
6
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.急性冠脉综合征后转换双联抗血小板治疗的获益：TOPIC（急性冠脉综合征后血小板抑制的时机）随机研究。
Eur Heart J. 2017 Nov 1;38(41):3070-3078. doi: 10.1093/eurheartj/ehx175.
7
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.经支架植入和随后双联抗血小板治疗（PRECISE-DAPT）的患者预测出血并发症的预测评分的推导和验证：来自临床试验的个体患者数据集的汇总分析。
Lancet. 2017 Mar 11;389(10073):1025-1034. doi: 10.1016/S0140-6736(17)30397-5.
8
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.替格瑞洛联合阿司匹林或单独用于冠状动脉介入术后高危患者：TWILIGHT研究的原理与设计
Am Heart J. 2016 Dec;182:125-134. doi: 10.1016/j.ahj.2016.09.006. Epub 2016 Sep 28.
9
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.经药物洗脱支架 PCI 术后的冠状动脉血栓形成和大出血：PARIS 风险评分。
J Am Coll Cardiol. 2016 May 17;67(19):2224-2234. doi: 10.1016/j.jacc.2016.02.064. Epub 2016 Apr 11.
10
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗1年后双联抗血小板治疗获益与风险预测规则的制定与验证
JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775.